Crizotinib: from discovery to accelerated development to front-line treatment
Authors:
- 29 August 2016
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 27 (suppl_3) , iii35-iii41
Abstract
Non-small-cell lung cancer (NSCLC) is associated with a poor prognosis and low survival rates, providing a strong rationale for the development of new treatment options. The discovery of ALK gene rearrangements in a subset of NSCLC specimens and the identification and development of the first-in-class ALK inhibitor crizotinib provided a personalised treatment option for patients with advanced ALK-positive NSCLC. Crizotinib demonstrated rapid and durable responses in advanced ALK-positive NSCLC patients in phase I and II studies, leading to accelerated FDA approval. Subsequent evaluation in phase III studies showed that crizotinib improved progression-free survival compared with platinum-based doublet chemotherapy in previously untreated patients and compared with pemetrexed or docetaxel in previously treated patients. Crizotinib was shown to have an acceptable safety profile and also to improve quality of life and symptom scores. Overall, crizotinib has been shown to provide a valuable first- and second-line treatment option and is now the first-line standard of care for patients with advanced ALK-positive NSCLC.Keywords
Funding Information
- Italian Association for Cancer Research
- Fondazione Ricerca Traslazionale
- Cancer Research UK Lung Centre of Excellence Grant Funding
- Italian Association for Cancer Research
- Fondazione Ricerca Traslazionale
- Cancer Research UK Lung Centre of Excellence Grant Funding
This publication has 43 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- Emerging Options for the Management of Non-Small Cell Lung CancerClinical Medicine Insights: Oncology, 2013
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Lung Cancer: Epidemiology, Etiology, and PreventionClinics in Chest Medicine, 2011
- Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on PemetrexedJournal of Thoracic Oncology, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Anaplastic lymphoma kinase: signalling in development and diseaseBiochemical Journal, 2009
- Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung CancerCell, 2007
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002